Hanmi Pharm Promises New Treatment for Patients with Extremely Rare Disease
Attended CHI patient meeting in the Netherlands
Adolescent patients with congenital hyperinsulinism (CHI) shared their experiences with one another at the 2023 Congenital Hyperinsulinism Family Conference in The Hague, Netherlands (left), while a pediatric CHI patients put on a performance.
Hanmi Pharmaceutical met with overseas patients suffering from an extremely rare disease to share their pain and expressed their commitment to developing an innovative treatment.
According to the company’s announcement on October 8, Hanmi Pharm participated in a symposium hosted by the Congenital Hyperinsulinism International (CHI) in The Hague, the Netherlands from September 22 to 24 and introduced LAPS Glucagon Analog (HM15136), which is currently under development as a new drug for congenital hyperinsulinism. They also discussed the direction of development with world-renowned experts.
CHI is a non-profit organization founded in 2005 to improve the lives of patients suffering from congenital hyperinsulinism.
Congenital hyperinsulinism is a rare disease that affects about 1 in 25,000 to 50,000 people. To date, there has been one approved treatment, but due to the low response rate, patients are inclined to use off-label medicines or rely on surgery to remove the pancreas despite side effects. The disease, the onset of which usually occurs in the neonatal period, causes severe and persistent hypoglycemia, which makes it difficult for the patient and their family.
Hanmi Pharm is developing a new drug as a once-weekly formulation to address the limitations of existing treatments, and a global Phase II clinical trial is currently underway. Hanmi’s platform technology called LAPSCOVERY has been applied to increase the drug efficacy and lower the dosing frequency, thereby improving the short half-life of glucagon that promotes the synthesis of glucose in the body.
“Although there is currently a standard treatment, considering that it has been associated with various side effects and poor efficacy in some of the patients, HM15136 seems to have sufficient potential as a groundbreaking new drug,” said Dr. Klaus L. Mohnike, a professor at Otto-von-Guericke-University Magdeburg in Germany.
Noh Yeong-su, CS Teamleader at Hanmi Pharm, who participated in the event, said, “By speaking with patients suffering from congenital hyperinsulinism in person, I was able to empathize with their pain and suffering. […] We will do our best to commercialize HM15136 as soon as possible.”